Cardiol Therapeutics (CRDL) Stock Price, News & Analysis

Company Overview

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Key Stats

• Today's Range: C$2.15 to C$2.30
• 50-Day Range: C$2.18 to C$3.37
• 52-Week Range: C$1.07 to C$4.26
• Volume: 134,722 shs
• Average Volume: 138,713 shs
• Market Capitalization: C$152.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

CRDL Stock Analysis - Frequently Asked Questions

How have CRDL shares performed this year?

Cardiol Therapeutics' stock was trading at C$1.10 at the beginning of the year. Since then, CRDL shares have increased by 98.2% and is now trading at C$2.18.
View the best growth stocks for 2024 here.

How do I buy shares of Cardiol Therapeutics?

Shares of CRDL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Cardiol Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiol Therapeutics investors own include Cardiol Therapeutics (CRTPF), Rolls-Royce Holdings plc (RR.L), Very Good Food (VRYYF), Gilead Sciences (GILD), Impel Pharmaceuticals (IMPL), Luminar Technologies (LAZR) and Meta Platforms (META).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: TSE:CRDL
• CUSIP: N/A
• CIK: N/A
• Web: www.cardiolrx.com
• Phone: 289 910 0850
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-29,340,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -108.43%
• Return on Assets: -54.15%

Debt

• Debt-to-Equity Ratio: 1.07
• Current Ratio: 2.39
• Quick Ratio: 6.84

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$2.22 per share
• Price / Cash Flow: 0.98
• Book Value: C$0.22 per share
• Price / Book: 9.91

Miscellaneous

• Outstanding Shares: 69,880,000
• Free Float: N/A
• Market Cap: C$152.34 million
• Optionable: Not Optionable
• Beta: 0.70